Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
168 SEK | +0.24% | +5.00% | +25.65% |
Apr. 25 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 48.67 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.65% | 1.22B | B+ | ||
-15.28% | 18.56B | A | ||
-44.98% | 2.71B | C+ | ||
+17.00% | 1.85B | - | - | |
-0.51% | 1.66B | - | ||
-13.90% | 989M | - | ||
-21.76% | 896M | - | C- | |
-3.53% | 745M | - | ||
-20.73% | 660M | B+ | ||
+6.37% | 490M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOT Stock
- Ratings Biotage AB